The Thyroid Patient Advocacy-UK (TPA-UK) Response to: “A Statement from the British Thyroid Association Executive Committee on Armour® Thyroid”
TPA-UK disagrees with many of the statements made by the Executive Committee of the British Thyroid Association (BTA) on natural desiccated porcine thyroid extract (Armour® Thyroid, USP). TPA-UK are very concerned that the BTA continue to advise that L-thyroxine (T4)-replacement remains the treatment of choice despite the amount of evidence contrary to their opinion, showing it to be ineffective in relieving many patients' symptoms. This research paper extensively refutes the incorrect and inaccurate BTA statements on Armour Thyroid.

Warning:
The BTA statements included in this paper deal with hypothyroidism as deficient thyroid secretion only. It has no bearing on deficient post-thyroid operations upon thyroid hormones.

The Thyroid Patient Advocacy –UK (TPA-UK) response to the British Thyroid Association’s (BTA) Statement on the Use of Combination Thyroxine/Triiodothyronine (Liothyronine) Therapy
TPA-UK believes that the experience of patients is not being considered in the diagnosis and treatment of hypothyroidism, and NHS doctors fail to offer alternative therapy if L-thyroxine is ineffective in resolving symptoms or is poorly tolerated by patients. Although ‘evidence based medicine’ is to be applauded, much of the evidence base for the treatment of hypothyroidism is based on research that does not consider the patient’s experience and may be flawed. This research paper refutes the BTA's incorrect and inaccurate statements regarding combination T4/T3 therapy.

Warning:
The BTA statements included in this paper deal with hypothyroidism as deficient thyroid secretion only. It has no bearing on deficient post-thyroid operations upon thyroid hormones.